Page last updated: 2024-09-05

tolvaptan and Kidney Neoplasms

tolvaptan has been researched along with Kidney Neoplasms in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Calvet, JP; Dwivedi, N; Enders, J; Jamadar, A; Kakade, VR; Neil, MO; Rao, R; Sinha, S; Tao, S; Thomas, SM; Weiss, RH	1
Gaur, P; Gedroyc, W; Hill, P	1
Angelini, C; Arosio, P; Bertuzzi, A; Colombo, P; Cucchiari, D; De Sanctis, R; Faucher, E; Fusco, N; Pellegrinelli, A	1

Reviews

1 review(s) available for tolvaptan and Kidney Neoplasms

Article	Year
ADPKD-what the radiologist should know. The British journal of radiology, 2019, Volume: 92, Issue:1098 Topics: Antidiuretic Hormone Receptor Antagonists; Carcinoma, Renal Cell; Cysts; Diagnosis, Differential; Diagnostic Imaging; Disease Progression; Humans; Kidney Calculi; Kidney Neoplasms; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2019

Other Studies

2 other study(ies) available for tolvaptan and Kidney Neoplasms

Article	Year
Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy. Oncogene, 2020, Volume: 39, Issue:6 Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Apoptosis; Biomarkers, Tumor; Carcinoma, Renal Cell; Case-Control Studies; Cell Cycle; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Mice; Mice, Nude; Prognosis; Receptors, Vasopressin; Tolvaptan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2020
Juxtaglomerular cell tumor: multicentric synchronous disease associated with paraneoplastic syndrome. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, May-10, Volume: 31, Issue:14 Topics: Antidiuretic Hormone Receptor Antagonists; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Dacarbazine; Deoxycytidine; Diagnosis, Differential; Disease Progression; Doxorubicin; Gemcitabine; Humans; Hyponatremia; Ifosfamide; Immunohistochemistry; Immunophenotyping; Inappropriate ADH Syndrome; Juxtaglomerular Apparatus; Kidney Neoplasms; Luminescent Measurements; Male; Middle Aged; Neoplasms, Multiple Primary; Paclitaxel; Paraneoplastic Syndromes; Renin; Tolvaptan; Vinblastine; Vinorelbine	2013

Article

Year

Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy.

Oncogene, 2020, Volume: 39, Issue:6

Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Apoptosis; Biomarkers, Tumor; Carcinoma, Renal Cell; Case-Control Studies; Cell Cycle; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Mice; Mice, Nude; Prognosis; Receptors, Vasopressin; Tolvaptan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2020

Juxtaglomerular cell tumor: multicentric synchronous disease associated with paraneoplastic syndrome.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, May-10, Volume: 31, Issue:14

Topics: Antidiuretic Hormone Receptor Antagonists; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Dacarbazine; Deoxycytidine; Diagnosis, Differential; Disease Progression; Doxorubicin; Gemcitabine; Humans; Hyponatremia; Ifosfamide; Immunohistochemistry; Immunophenotyping; Inappropriate ADH Syndrome; Juxtaglomerular Apparatus; Kidney Neoplasms; Luminescent Measurements; Male; Middle Aged; Neoplasms, Multiple Primary; Paclitaxel; Paraneoplastic Syndromes; Renin; Tolvaptan; Vinblastine; Vinorelbine

2013